Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Mineralys Therapeutics (NASDAQ: MLYS) has announced a key opinion leader (KOL) conference call and webinar scheduled for Tuesday, April 1, 2025, at 8:00 AM ET. The event will feature Dr. Luke Laffin from the Cleveland Clinic, who will present and discuss the latest results from two pivotal clinical trials: Advance-HTN and Launch-HTN.
The presentation will focus on lorundrostat's potential in treating uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). Dr. Laffin will also address the current unmet medical needs in these conditions and how lorundrostat could potentially transform the existing treatment approach.
The event will be accessible via webcast through the Investor Relations section of Mineralys Therapeutics' website under the 'News & Events' page.
Mineralys Therapeutics (NASDAQ: MLYS) ha annunciato una conferenza telefonica con leader d'opinione (KOL) e un webinar programmati per martedì 1 aprile 2025, alle 8:00 AM ET. L'evento presenterà Dr. Luke Laffin della Cleveland Clinic, che presenterà e discuterà gli ultimi risultati di due studi clinici fondamentali: Advance-HTN e Launch-HTN.
La presentazione si concentrerà sul potenziale di lorundrostat nel trattamento dell'ipertensione non controllata (uHTN) e dell'ipertensione resistente (rHTN). Il Dr. Laffin affronterà anche i bisogni medici non soddisfatti attuali in queste condizioni e come lorundrostat potrebbe trasformare l'approccio terapeutico esistente.
L'evento sarà accessibile tramite webcast nella sezione Relazioni con gli Investitori del sito web di Mineralys Therapeutics, nella pagina 'Notizie e Eventi'.
Mineralys Therapeutics (NASDAQ: MLYS) ha anunciado una conferencia telefónica con líderes de opinión (KOL) y un seminario web programado para el martes 1 de abril de 2025, a las 8:00 AM ET. El evento contará con Dr. Luke Laffin de la Cleveland Clinic, quien presentará y discutirá los últimos resultados de dos ensayos clínicos clave: Advance-HTN y Launch-HTN.
La presentación se centrará en el potencial de lorundrostat para tratar la hipertensión no controlada (uHTN) y la hipertensión resistente (rHTN). El Dr. Laffin también abordará las necesidades médicas insatisfechas actuales en estas condiciones y cómo lorundrostat podría transformar el enfoque de tratamiento existente.
El evento será accesible a través de una transmisión web en la sección de Relaciones con Inversores del sitio web de Mineralys Therapeutics, en la página 'Noticias y Eventos'.
미네랄리스 테라퓨틱스 (NASDAQ: MLYS)는 2025년 4월 1일 화요일 오전 8시(ET)에 예정된 주요 의견 리더(KOL) 전화 회의 및 웨비나를 발표했습니다. 이 이벤트에는 클리블랜드 클리닉의 Dr. Luke Laffin이 참여하여 두 가지 주요 임상 시험인 Advance-HTN과 Launch-HTN의 최신 결과를 발표하고 논의할 것입니다.
발표는 조절되지 않는 고혈압(uHTN) 및 저항성 고혈압(rHTN) 치료에 있어 lorundrostat의 잠재력에 초점을 맞출 것입니다. Laffin 박사는 또한 이러한 상태에서 현재 충족되지 않은 의료 요구 사항과 lorundrostat이 기존 치료 접근 방식을 어떻게 변화시킬 수 있는지에 대해 설명할 것입니다.
이 이벤트는 미네랄리스 테라퓨틱스 웹사이트의 투자자 관계 섹션 '뉴스 및 이벤트' 페이지를 통해 웹캐스트로 접근할 수 있습니다.
Mineralys Therapeutics (NASDAQ: MLYS) a annoncé une conférence téléphonique avec des leaders d'opinion (KOL) et un webinaire prévu pour le mardi 1er avril 2025, à 8h00 ET. L'événement mettra en vedette Dr. Luke Laffin de la Cleveland Clinic, qui présentera et discutera des derniers résultats de deux essais cliniques pivots : Advance-HTN et Launch-HTN.
La présentation se concentrera sur le potentiel du lorundrostat dans le traitement de l'hypertension incontrôlée (uHTN) et de l'hypertension résistante (rHTN). Le Dr. Laffin abordera également les besoins médicaux non satisfaits actuels dans ces conditions et comment le lorundrostat pourrait potentiellement transformer l'approche thérapeutique existante.
L'événement sera accessible par webcast via la section Relations Investisseurs du site web de Mineralys Therapeutics sous la page 'Actualités et Événements'.
Mineralys Therapeutics (NASDAQ: MLYS) hat eine Telefonkonferenz mit Meinungsführern (KOL) und ein Webinar für Dienstag, den 1. April 2025, um 8:00 Uhr ET angekündigt. Bei der Veranstaltung wird Dr. Luke Laffin von der Cleveland Clinic auftreten, der die neuesten Ergebnisse aus zwei entscheidenden klinischen Studien präsentieren und diskutieren wird: Advance-HTN und Launch-HTN.
Die Präsentation wird sich auf das Potenzial von Lorundrostat bei der Behandlung von unkontrollierter Hypertonie (uHTN) und resistenter Hypertonie (rHTN) konzentrieren. Dr. Laffin wird auch die aktuellen unerfüllten medizinischen Bedürfnisse in diesen Zuständen ansprechen und wie Lorundrostat den bestehenden Behandlungsansatz möglicherweise transformieren könnte.
Die Veranstaltung wird über einen Webcast im Bereich Investor Relations der Website von Mineralys Therapeutics unter der Seite 'News & Events' zugänglich sein.
- None.
- None.
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension
RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar featuring Dr. Luke Laffin of the Cleveland Clinic, who will discuss the latest results from the pivotal Advance-HTN and Launch-HTN clinical trials, and offer his perspective on the unmet medical need in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), and the potential of lorundsrostat to change the current treatment paradigm.
| Tuesday, April 1st @ 8:00 a.m. ET | |||
| Domestic: | 1-877-704-4453 | ||
| International: | 1-201-389-0920 | ||
| Webcast: | Link | ||
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When is Mineralys Therapeutics (MLYS) hosting the KOL conference call on lorundrostat trials?
Which clinical trials will be discussed during the MLYS KOL webinar?
Who is the key speaker at the Mineralys Therapeutics (MLYS) clinical data presentation?
What medical conditions is Mineralys Therapeutics (MLYS) targeting with lorundrostat?
